Therapy Gains Ground as a Go-To Solution for Everyday Stress and Social Connection Modern Health, a global workplace mental health platform, has released new international research examining how employees use therapy and other forms of mental health support. The survey…
Alkermes Reports Positive Phase 1 Results for Investigational Orexin 2 Receptor Agonist ALKS 7290 in Adult ADHD Alkermes plc (Nasdaq: ALKS) has announced positive topline results from a Phase 1 proof-of-concept study evaluating ALKS 7290, a novel investigational orexin 2…
Bristol Myers Squibb Reports Two-Year Data Showing Durable Sotyktu Efficacy in Psoriatic Arthritis Bristol Myers Squibb (NYSE: BMY) announced positive two-year results from the Phase 3 POETYK PsA-2 study and its open-label extension (OLE), providing additional evidence of durable efficacy…
IMPACT Therapeutics’ Senaparib Receives Positive EMA CHMP Opinion for Ovarian Cancer Maintenance Treatment IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on developing targeted anti-cancer therapies based on synthetic lethality mechanisms, and global specialty pharmaceutical company Pharmanovia have announced a…
Largest Lung Cancer MRD Study Demonstrates Signatera™’s Strong Prognostic Value Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, has announced new clinical data presented at the IASLC 2026 World Conference on Lung Cancer (WCLC)…
PAHO-Gilead HIV Prevention Deal in Latin America Welcomed by AHF as Civil Society Victory AIDS Healthcare Foundation (AHF), one of the world’s largest HIV/AIDS healthcare organizations, has welcomed a new agreement between Gilead Sciences and the Pan American Health Organization…
NImmune Biopharma to Present Clinical and Preclinical Data on NIM-1324 at ACG 2026, Highlighting LANCL2 Potential in Difficult-to-Treat IBD NImmune Biopharma, a private, late-stage precision inflammation and immunology (I&I) biopharmaceutical company, is set to present two studies at the American…
IMDELLTRA® Plus IMFINZI® Shows Landmark Overall Survival Benefit in First-Line Extensive-Stage Small Cell Lung Cancer Amgen (NASDAQ: AMGN) announced landmark results from the Phase 3 DeLLphi-305 study, reporting that the trial met its primary endpoint at a pre-specified interim analysis…
Johnson & Johnson to Present 24 Neuropsychiatry Data Sets at Psych Congress 2026 Johnson & Johnson (NYSE: JNJ) will present 24 abstracts featuring clinical trial data and real-world evidence from across its neuropsychiatry portfolio at the 2026 Psych Congress Annual…
Strata Mental Health Solutions Awarded Compass Pathways Grant to Develop U.S. Provider Training for COMP360 Strata Mental Health Solutions, an expert-led training and implementation partner focused on preparing clinical networks to deliver regulated psychedelic treatments, has been selected as one…
Bausch + Lomb Receives European CE Mark for Next-Generation SeeLyra Femtosecond Laser Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global eye health company focused on helping people see better and live better, has announced that its next-generation SeeLyra femtosecond laser…
Johnson & Johnson Receives CE Mark for ACUVUE OASYS MAX 2-Week Reusable Contact Lens Johnson & Johnson (NYSE: JNJ) announced that it has received CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens designed to provide enhanced…